In Vitro Activity of 2,4-Diamino-6-[2-(Phosphonomethoxy)Ethoxy]-Pyrimidine against Multidrug-Resistant Hepatitis B Virus Mutants
-
- M. N. Brunelle
- INSERM, U871, 151 Cours Albert Thomas, 69003 Lyon, France
-
- J. Lucifora
- INSERM, U871, 151 Cours Albert Thomas, 69003 Lyon, France
-
- J. Neyts
- Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
-
- S. Villet
- INSERM, U871, 151 Cours Albert Thomas, 69003 Lyon, France
-
- A. Holy
- Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic
-
- C. Trepo
- INSERM, U871, 151 Cours Albert Thomas, 69003 Lyon, France
-
- F. Zoulim
- INSERM, U871, 151 Cours Albert Thomas, 69003 Lyon, France
書誌事項
- 公開日
- 2007-06
- 権利情報
-
- https://journals.asm.org/non-commercial-tdm-license
- DOI
-
- 10.1128/aac.01440-06
- 公開者
- American Society for Microbiology
この論文をさがす
説明
<jats:title>ABSTRACT</jats:title><jats:p>The susceptibilities of drug-resistant hepatitis B virus (HBV) mutants to lamivudine, adefovir, tenofovir, entecavir, and 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine (PMEO-DAPym), a novel acyclic pyrimidine analogue, were assessed in vitro. Most drug-resistant mutants, including multidrug-resistant strains, remained sensitive to tenofovir and PMEO-DAPym. Therefore, the latter molecule deserves further evaluation for the treatment of HBV infection.</jats:p>
収録刊行物
-
- Antimicrobial Agents and Chemotherapy
-
Antimicrobial Agents and Chemotherapy 51 (6), 2240-2243, 2007-06
American Society for Microbiology
